IPO registrations (S-1, F-1) · Registrants
EOM Pharmaceutical Holdings, Inc.
- SEC CIK
- 822411 · filings on EDGAR ↗
- Former names
- ImmunoCellular Therapeutics, Ltd. (2006–2022); Optical Molecular Imaging, Inc (2006–2006); PATCO INDUSTRIES LTD (1999–2006)
- Registration
- Form S-1, first filed 2008-04-16, last 2022-12-20; 9 initial registrations, 15 amendments
- Outcome
- Final prospectus filed 2012-01-11; declared effective 2008-05-05; withdrawal requested 2023-08-02
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 30721 RUSSELL RANCH ROAD, SUITE 140, Westlake Village, CA 91362
- EIN
- 93-1301885
- EDGAR entity type
- operating
- Insiders and CEO pay
- EOM Pharmaceutical Holdings, Inc. on the corporate pages
Offering terms
- Final price
- $1.10 per share (424B4 filed 2012-01-11)
- Shares sold
- 9,489,436
- Gross proceeds
- $10,438,379 before underwriting discounts and any over-allotment option
- Listing
- OTC under the symbol IMUC
- Lead underwriters
- Cowen
- Syndicate
- Summer Street Research Partners
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: IMMUNOCELLULAR THERAPEUTICS, LTD. EXACT (EIN (EXACT))
- Form D issuer: ImmunoCellular Therapeutics, Ltd. EXACT (CIK (EXACT))
- SEC filer: ImmunoCellular Therapeutics, Ltd. EXACT (CIK (EXACT))
Filings 54
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2008-04-16 | S-1 | S-1 (registration) | ImmunoCellular Therapeutics, Ltd. | 0001193125-08-082842 ↗ |
| 2008-05-05 | EFFECT | EFFECT (declared effective) | ImmunoCellular Therapeutics, Ltd. | 9999999995-08-001450 ↗ |
| 2008-05-13 | EFFECT | EFFECT (declared effective) | ImmunoCellular Therapeutics, Ltd. | 9999999995-08-001543 ↗ |
| 2009-05-14 | EFFECT | EFFECT (declared effective) | ImmunoCellular Therapeutics, Ltd. | 9999999995-09-001402 ↗ |
| 2009-06-19 | EFFECT | EFFECT (declared effective) | ImmunoCellular Therapeutics, Ltd. | 9999999995-09-001706 ↗ |
| 2009-12-23 | S-1 | S-1 (registration) | ImmunoCellular Therapeutics, Ltd. | 0001193125-09-259142 ↗ |
| 2010-01-22 | EFFECT | EFFECT (declared effective) | ImmunoCellular Therapeutics, Ltd. | 9999999995-10-000296 ↗ |
| 2010-05-28 | S-1 | S-1 (registration) | ImmunoCellular Therapeutics, Ltd. | 0000950130-10-001484 ↗ |
| 2010-06-23 | EFFECT | EFFECT (declared effective) | ImmunoCellular Therapeutics, Ltd. | 9999999995-10-001914 ↗ |
| 2010-07-06 | EFFECT | EFFECT (declared effective) | ImmunoCellular Therapeutics, Ltd. | 9999999995-10-002045 ↗ |
| 2010-07-06 | EFFECT | EFFECT (declared effective) | ImmunoCellular Therapeutics, Ltd. | 9999999995-10-002048 ↗ |
| 2010-10-13 | EFFECT | EFFECT (declared effective) | ImmunoCellular Therapeutics, Ltd. | 9999999995-10-002911 ↗ |
| 2011-04-05 | S-1 | S-1 (registration) | ImmunoCellular Therapeutics, Ltd. | 0001193125-11-089221 ↗ |
| 2011-04-26 | EFFECT | EFFECT (declared effective) | ImmunoCellular Therapeutics, Ltd. | 9999999995-11-001161 ↗ |
| 2011-04-26 | EFFECT | EFFECT (declared effective) | ImmunoCellular Therapeutics, Ltd. | 9999999995-11-001170 ↗ |
| 2011-05-12 | EFFECT | EFFECT (declared effective) | ImmunoCellular Therapeutics, Ltd. | 9999999995-11-001498 ↗ |
| 2011-11-29 | S-1 | S-1 (registration) | ImmunoCellular Therapeutics, Ltd. | 0001193125-11-324516 ↗ |
| 2011-12-09 | S-1/A | S-1/A (amendment) | ImmunoCellular Therapeutics, Ltd. | 0001193125-11-335356 ↗ |
| 2011-12-22 | S-1/A | S-1/A (amendment) | ImmunoCellular Therapeutics, Ltd. | 0001193125-11-350921 ↗ |
| 2011-12-29 | S-1/A | S-1/A (amendment) | ImmunoCellular Therapeutics, Ltd. | 0001193125-11-355719 ↗ |
| 2011-12-30 | EFFECT | EFFECT (declared effective) | ImmunoCellular Therapeutics, Ltd. | 9999999995-12-000026 ↗ |
| 2012-01-11 | 424B4 | 424B4 (final prospectus) | ImmunoCellular Therapeutics, Ltd. | 0001193125-12-008271 ↗ |
| 2012-05-09 | EFFECT | EFFECT (declared effective) | ImmunoCellular Therapeutics, Ltd. | 9999999995-12-001469 ↗ |
| 2012-05-09 | EFFECT | EFFECT (declared effective) | ImmunoCellular Therapeutics, Ltd. | 9999999995-12-001472 ↗ |
| 2012-05-09 | EFFECT | EFFECT (declared effective) | ImmunoCellular Therapeutics, Ltd. | 9999999995-12-001476 ↗ |
| 2012-06-25 | EFFECT | EFFECT (declared effective) | ImmunoCellular Therapeutics, Ltd. | 9999999995-12-001925 ↗ |
| 2012-10-09 | EFFECT | EFFECT (declared effective) | ImmunoCellular Therapeutics, Ltd. | 9999999995-12-002933 ↗ |
| 2014-12-12 | S-1 | S-1 (registration) | ImmunoCellular Therapeutics, Ltd. | 0001193125-14-440396 ↗ |
| 2015-01-21 | S-1/A | S-1/A (amendment) | ImmunoCellular Therapeutics, Ltd. | 0001193125-15-016355 ↗ |
| 2015-02-10 | S-1/A | S-1/A (amendment) | ImmunoCellular Therapeutics, Ltd. | 0001193125-15-039761 ↗ |
| 2015-02-11 | S-1/A | S-1/A (amendment) | ImmunoCellular Therapeutics, Ltd. | 0001193125-15-044137 ↗ |
| 2015-02-11 | EFFECT | EFFECT (declared effective) | ImmunoCellular Therapeutics, Ltd. | 9999999995-15-000389 ↗ |
| 2015-02-12 | 424B4 | 424B4 (final prospectus) | ImmunoCellular Therapeutics, Ltd. | 0001193125-15-045685 ↗ |
| 2016-01-19 | EFFECT | EFFECT (declared effective) | ImmunoCellular Therapeutics, Ltd. | 9999999995-16-003541 ↗ |
| 2016-06-01 | S-1 | S-1 (registration) | ImmunoCellular Therapeutics, Ltd. | 0001628280-16-016887 ↗ |
| 2016-07-11 | S-1/A | S-1/A (amendment) | ImmunoCellular Therapeutics, Ltd. | 0001628280-16-017552 ↗ |
| 2016-08-03 | S-1/A | S-1/A (amendment) | ImmunoCellular Therapeutics, Ltd. | 0001628280-16-018311 ↗ |
| 2016-08-04 | S-1/A | S-1/A (amendment) | ImmunoCellular Therapeutics, Ltd. | 0001628280-16-018428 ↗ |
| 2016-08-04 | EFFECT | EFFECT (declared effective) | ImmunoCellular Therapeutics, Ltd. | 9999999995-16-005347 ↗ |
| 2016-08-08 | EFFECT | EFFECT (declared effective) | ImmunoCellular Therapeutics, Ltd. | 9999999995-16-005376 ↗ |
| 2016-08-11 | 424B4 | 424B4 (final prospectus) | ImmunoCellular Therapeutics, Ltd. | 0001628280-16-018870 ↗ |
| 2016-08-15 | EFFECT | EFFECT (declared effective) | ImmunoCellular Therapeutics, Ltd. | 9999999995-16-005441 ↗ |
| 2016-12-28 | S-1 | S-1 (registration) | ImmunoCellular Therapeutics, Ltd. | 0001628280-16-022164 ↗ |
| 2017-04-04 | S-1/A | S-1/A (amendment) | ImmunoCellular Therapeutics, Ltd. | 0001628280-17-003307 ↗ |
| 2017-06-12 | S-1/A | S-1/A (amendment) | ImmunoCellular Therapeutics, Ltd. | 0001628280-17-006359 ↗ |
| 2017-07-10 | S-1/A | S-1/A (amendment) | ImmunoCellular Therapeutics, Ltd. | 0001628280-17-006965 ↗ |
| 2017-07-13 | S-1/A | S-1/A (amendment) | ImmunoCellular Therapeutics, Ltd. | 0001628280-17-007028 ↗ |
| 2017-07-17 | EFFECT | EFFECT (declared effective) | ImmunoCellular Therapeutics, Ltd. | 9999999995-17-001832 ↗ |
| 2017-07-20 | 424B4 | 424B4 (final prospectus) | ImmunoCellular Therapeutics, Ltd. | 0001628280-17-007150 ↗ |
| 2018-11-15 | EFFECT | EFFECT (declared effective) | ImmunoCellular Therapeutics, Ltd. | 9999999995-18-002892 ↗ |
| 2022-06-24 | S-1 | S-1 (registration) | ImmunoCellular Therapeutics, Ltd. | 0001493152-22-017701 ↗ |
| 2022-08-10 | S-1/A | S-1/A (amendment) | ImmunoCellular Therapeutics, Ltd. | 0001493152-22-021859 ↗ |
| 2022-12-20 | S-1/A | S-1/A (amendment) | EOM Pharmaceutical Holdings, Inc. | 0001493152-22-035920 ↗ |
| 2023-08-02 | RW | RW (withdrawal request) | EOM Pharmaceutical Holdings, Inc. | 0001493152-23-026431 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2011-12-29 | S-1/A | registration statement | $1.07 | 10,000,000 | $10,700,000 | OTC IMUC | 2 | primary document; price line, shares headline, proceeds computed, cover names 2 | document ↗ | |
| 2012-01-11 | 424B4 | final prospectus | $1.10 | 9,489,436 | $10,438,379 | OTC IMUC | 2 | primary document; price sentence, shares headline, proceeds computed, cover names 2 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Bender James G. | Officer | VP Product Development & Mfg.; VP, Product Development & Mfg. | 7 | 2012–2013 | |
| BRANDWYNNE JACQUELINE | Director | 1 | 2012 | ||
| Chin Richard | Director | 4 | 2012–2014 | ||
| COWELL RICHARD | Director | 3 | 2012–2013 | ||
| FRACTOR DAVID | Officer | Chief Financial Officer; Principal Accounting Officer; See Remarks; VP of Finance | 7 | 2012–2016 | |
| Kim Helen Susan | Director | 4 | 2012–2014 | ||
| Singh Manish | Director,Officer | President & CEO | 1 | 2012 | |
| Singhvi Rahul | Director | 7 | 2012–2016 | ||
| Yu John S | Director; Director,Officer | Secretary; See Remarks | 13 | 2012–2018 | |
| Gengos Andrew | Director; Director,Officer | President and CEO | 12 | 2012–2017 | |
| Titus Gary | Director; Director,Officer | Chairman and Secretary | 8 | 2013–2016 | |
| Gringeri Anthony | Officer | Senior VP Strategic Resources; Sr. VP, Strategic Resources | 9 | 2013–2016 | |
| Swanson Steven J | Officer | Senior Vice President, Researc | 3 | 2015–2016 | |
| LAPOINTE ANTHONY GREGG | Director | 3 | 2015–2016 | ||
| SCHLOSSBERG MARK A | Director | 3 | 2015–2016 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2022-09-12 | ImmunoCellular Therapeutics, Ltd. | Pharmaceuticals | $5,000,000 | $750,000 | 1 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Plan sponsor | IMMUNOCELLULAR THERAPEUTICS, LTD. | CA | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Form D issuer | ImmunoCellular Therapeutics, Ltd. | NJ | Form D private offerings | CIK (EXACT) |
| SEC filer | ImmunoCellular Therapeutics, Ltd. | SEC filers (EDGAR) | CIK (EXACT) | |
| Form 5500 plan sponsor | IMMUNOCELLULAR THERAPEUTICS, LTD. | EIN (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, CA first:
- NovaCardia Inc CA
- MyoKardia, Inc. CA
- Bioquest Corp CA
- Regen BioPharma Inc CA
- CONNETICS CORP CA
- SIBIA NEUROSCIENCES INC CA
- MEDIVATION, INC. CA
- IMMUSOL INC CA
- DYNAVAX TECHNOLOGIES CORP CA
- Diadexus, Inc. CA
In other datasets, the same topic (Health) in CA:
- Nonprofit: 24 HOUR CANCER DANCE-A-THON (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health